Cwm, LLC Enanta Pharmaceuticals Inc Transaction History

Cwm, LLC

$23.3 Billion
Q3 2024

A detailed history of Cwm, LLC transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Cwm, LLC holds 336 shares of ENTA stock, worth $2,016. This represents 0.0% of its overall portfolio holdings.

Number of Shares

336

Previous 304 10.53%

Holding current value

$2,016

Previous $4,000 25.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 08, 2024	BUY	$10.05 - $16.54 $321 - $529	32 Added 10.53%	336 $3,000
Q2 2024 Jul 09, 2024	BUY	$11.43 - $17.02 $160 - $238	14 Added 4.83%	304 $4,000
Q1 2024 Apr 05, 2024	SELL	$10.08 - $17.46 $362 - $628	-36 Reduced 11.04%	290 $5,000
Q4 2023 Feb 01, 2024	SELL	$8.18 - $10.78 $9,603 - $12,655	-1,174 Reduced 78.27%	326 $3,000
Q3 2023 Oct 11, 2023	BUY	$11.09 - $22.13 $13,308 - $26,556	1,200 Added 400.0%	1,500 $17,000
Q2 2023 Aug 03, 2023	BUY	$20.68 - $39.85 $3,701 - $7,133	179 Added 147.93%	300 $6,000
Q1 2023 Apr 28, 2023	SELL	$38.82 - $54.59 $737 - $1,037	-19 Reduced 13.57%	121 $5,000
Q4 2022 Feb 01, 2023	BUY	$40.77 - $53.73 $3,383 - $4,459	83 Added 145.61%	140 $7,000
Q2 2022 Jul 28, 2022	BUY	$38.13 - $76.93 $2,059 - $4,154	54 Added 1800.0%	57 $3,000
Q1 2022 Apr 21, 2022	SELL	$56.06 - $74.11 $224 - $296	-4 Reduced 57.14%	3 $0
Q4 2021 Jan 31, 2022	SELL	$60.19 - $97.37 $1,143 - $1,850	-19 Reduced 73.08%	7 $1,000
Q4 2019 Jan 27, 2020	SELL	$57.95 - $66.61 $3,129 - $3,596	-54 Reduced 67.5%	26 $2,000
Q3 2019 Oct 22, 2019	BUY	$60.08 - $88.17 $4,806 - $7,053	80 New	80 $5,000

Others Institutions Holding ENTA

# of Institutions

110

Shares Held

21.1M

Call Options Held

4.8K

Put Options Held

4.6K

View Full List

About ENANTA PHARMACEUTICALS INC

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $124M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

More about ENTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account